ArticleBMC cancer2022

Validating ORR and PFS as surrogate endpoints in phase II and III clinical trials for NSCLC patients: difference exists in the strength of surrogacy in various trial settings.

Tiantian Hua et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.